Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Long-Term Immunological Consequences of CD19 CAR T Cell Therapy: Analysis of Infectious Complications and Immune Reconstitution

Andreas Riedel, Jan Frederic Weller, Laurent Phely, Stefan Hug, Christoph Faul, Claudia Lengerke, Wolfgang Andreas Bethge

Blood (2024) 144 (Supplement 1): 7248.

https://doi.org/10.1182/blood-2024-210536

Published: 2024

Journal Articles

Dual CD19/CD22-Targeting CAR-T Cells for Richter Transformation: A Case Series

Stefan Hug, Laurent Phely, Andreas Riedel, Simon Killinger, Luca Hensen, Christoph Faul, Wolfgang Andreas Bethge, Claudia Lengerke

Blood (2024) 144 (Supplement 1): 6544.

https://doi.org/10.1182/blood-2024-200768

Published: 2024

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Blood (2024) 144 (Supplement 1): 3554.

https://doi.org/10.1182/blood-2024-204560

Published: 2024

Journal Articles

Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2024) 144 (Supplement 1): 399.

https://doi.org/10.1182/blood-2024-210100

Published: 2024

Journal Articles

Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Blood (2024) 144 (Supplement 1): 3560.

https://doi.org/10.1182/blood-2024-210920

Published: 2024

Journal Articles

Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

Blood (2024) 144 (Supplement 1): 776.

https://doi.org/10.1182/blood-2024-204763

Published: 2024

Journal Articles

Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Blood (2024) 144 (Supplement 1): 965.

https://doi.org/10.1182/blood-2024-205669

Published: 2024

Journal Articles

Unrelated Donors below 35 Years of Age Should be Preferred over HLA-Matched Sibling Donors Older Than 50 Years for Patients with Myeloid Malignancies

Johannes Schetelig, Henning Baldauf, Carina Rave, Gesine Bug, Lutz Peter Hermann Mueller, Eva Wagner Drouet, Francis A. Ayuk, Wolfgang Andreas Bethge, Matthias Stelljes, Thomas Schröder, Desiree Kunadt, Katja Sockel, Jan Moritz Middeke, Daniel Fürst, Alexander H. Schmidt, Katharina Fleischhauer, Martin Bornhäuser

Blood (2023) 142 (Supplement 1): 1046.

https://doi.org/10.1182/blood-2023-180531

Published: 2023

Journal Articles

Patients with High-Risk Myelodysplastic Neoplasms Do Not Benefit from Remission Induction with Azacitidine Prior to Hematopoietic Cell Transplantation: A Retrospective, Single-Center Analysis with Extended Follow-up

Jan Christian Schröder, Jan Frederic Weller, Philipp Faustmann, Lucas Mix, Christoph Faul, Claudia Lengerke, Wolfgang Andreas Bethge

Blood (2023) 142 (Supplement 1): 2231.

https://doi.org/10.1182/blood-2023-174430

Published: 2023

Journal Articles

Interindividual HLA Evolutionary Divergence in Single HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation for Malignant Hematological Disorders: A Report on Behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 895.

https://doi.org/10.1182/blood-2023-187622

Published: 2023

Journal Articles

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Blood (2023) 142 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2023-174883

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplant Recipients Carrying DNMT3A and ASXL1 Mutations More Frequently Develop Severe Graft Versus Host Disease and Arterial Hypertension

Alisha Weiss-Haug, Reka A Haraszti, Britta Merz, Kristina Reuss, Christoph Faul, Wolfgang Andreas Bethge, Frederike Schwartz, Wichard Vogel, Claudia Lengerke

Blood (2023) 142 (Supplement 1): 3564.

https://doi.org/10.1182/blood-2023-188752

Published: 2023

Journal Articles

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Mueller, Wolfgang Andreas Bethge, Javier L. Munoz, Razan Mohty, Veit L. Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe

Blood (2023) 142 (Supplement 1): 359.

https://doi.org/10.1182/blood-2023-180607

Published: 2023

Journal Articles

Prospective Evaluation of Patient-Reported Outcome up to 10 Years after Allogeneic Stem Cell Transplantation Using FACT-G/BMT and EORTC-QLQ30 Questionnaires

Sina Alexandra Beer, Johanna Blaettel, Kristina Reuss, Jan Christian Schröder, Wichard Vogel, Christoph Faul, Wolfgang Andreas Bethge, Claudia Lengerke

Blood (2023) 142 (Supplement 1): 2208.

https://doi.org/10.1182/blood-2023-188833

Published: 2023

Journal Articles

How Much Have Post-Transplant Outcomes Improved Since 2000 for Older Patients with Acute Myeloid Leukemia? a Study from the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 896.

https://doi.org/10.1182/blood-2023-179489

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Adult Metachromatic Leukodystrophy (MLD): A Case Series

Andreas Riedel, Christoph Faul, Kristina Reuss, Peter Lang, Claudia Lengerke, Nadine Weissert, Holger Hengel, Ludger Schoels, Wolfgang Andreas Bethge

Blood (2023) 142 (Supplement 1): 7115.

https://doi.org/10.1182/blood-2023-187317

Published: 2023

Journal Articles

Chronic Graft-Versus-Host Disease: Lessons From a Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation (HSCT) From Matched Unrelated Donors

Gérard Socié, Claudia Schmoor, Wolfgang Andreas Bethge, Hellmut Ottinger, Matthias Stelljes, Axel R. Zander, MD, Liisa Volin, Dominik Heim, MD, Rainer Schwerdtfeger, MD, Hartmut Bertz, Olga Grishina, Jurgen Finke, MD

Blood (2010) 116 (21): 212.

https://doi.org/10.1182/blood.V116.21.212.212

Published: 2010

Journal Articles

Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Final Results and Analysis of Prognostic Factors

Jurgen Finke, MD, Claudia Schmoor, Wolfgang Andreas Bethge, Hellmut Ottinger, Matthias Stelljes, Axel R. Zander, MD, Liisa Volin, Dominik Heim, MD, Rainer Schwerdtfeger, MD, Hartmut Bertz, Olga Grishina, Gérard Socié

Blood (2010) 116 (21): 1249.

https://doi.org/10.1182/blood.V116.21.1249.1249

Published: 2010

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in AML: Comparable Results After Matched or Mismatched Unrelated Versus Matched Related Transplantation.

Birgit Federmann, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang Andreas Bethge, MD

Blood (2009) 114 (22): 1199.

https://doi.org/10.1182/blood.V114.22.1199.1199

Published: 2009

Journal Articles

Allogeneic Stem Cell Transplantation for Hodgkin's Disease From Sibling and Unrelated Donors: The German Cooperative Transplantation Study Group Experience.

Blood (2009) 114 (22): 2293.

https://doi.org/10.1182/blood.V114.22.2293.2293

Published: 2009

NARROW

Long-Term Immunological Consequences of CD19 CAR T Cell Therapy: Analysis of Infectious Complications and Immune Reconstitution

Dual CD19/CD22-Targeting CAR-T Cells for Richter Transformation: A Case Series

Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Unrelated Donors below 35 Years of Age Should be Preferred over HLA-Matched Sibling Donors Older Than 50 Years for Patients with Myeloid Malignancies

Patients with High-Risk Myelodysplastic Neoplasms Do Not Benefit from Remission Induction with Azacitidine Prior to Hematopoietic Cell Transplantation: A Retrospective, Single-Center Analysis with Extended Follow-up

Interindividual HLA Evolutionary Divergence in Single HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation for Malignant Hematological Disorders: A Report on Behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Allogeneic Hematopoietic Cell Transplant Recipients Carrying DNMT3A and ASXL1 Mutations More Frequently Develop Severe Graft Versus Host Disease and Arterial Hypertension

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Prospective Evaluation of Patient-Reported Outcome up to 10 Years after Allogeneic Stem Cell Transplantation Using FACT-G/BMT and EORTC-QLQ30 Questionnaires

How Much Have Post-Transplant Outcomes Improved Since 2000 for Older Patients with Acute Myeloid Leukemia? a Study from the EBMT Acute Leukemia Working Party

Allogeneic Hematopoietic Stem Cell Transplantation for Adult Metachromatic Leukodystrophy (MLD): A Case Series

Chronic Graft-Versus-Host Disease: Lessons From a Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation (HSCT) From Matched Unrelated Donors

Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Final Results and Analysis of Prognostic Factors

Allogeneic Hematopoietic Cell Transplantation in AML: Comparable Results After Matched or Mismatched Unrelated Versus Matched Related Transplantation.

Allogeneic Stem Cell Transplantation for Hodgkin's Disease From Sibling and Unrelated Donors: The German Cooperative Transplantation Study Group Experience.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only